zalypsis
Animal productexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2006 (NCT00359294)
Timeline
Indications
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- n-((5-(acetyloxy)-6,6a,7,13,14,16-hexahydro-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-7,13-imino-12h-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocin-16-yl)methyl)-3-(3-(trifluoromethyl)phenyl)-2e-propenamide
- n-(((6as,7r,13s,14s,16r)-5-(acetyloxy)-6,6a,7,13,14,16-hexahydro-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-7,13-imino-12h-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocin-16-yl)methyl)-3-(3-(trifluoromethyl)phenyl)-2e-propenamide
- pm00104
- pm 00104
- pm-00104
- zalypsis
- zalypsis
- zalypsis
- zalypsis
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01222767 | Phase 2 | Dec 1, 2010 | Centre Leon Berard, Istituto Clinico Humanitas - Rozzano (MI), Italy, PharmaMar, St. Jude Children's Hospital, University of Bologna, University of Milan, University of Washington |
| NCT00900562 | Phase 2 | Aug 1, 2009 | PharmaMar |
| NCT00359294 | Phase 1 | May 1, 2006 | PharmaMar, Temple University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PharmaMar | For profit | 3 | 3 | 2 | 2006 |
| Centre Leon Berard | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Istituto Clinico Humanitas - Rozzano (MI), Italy | Academic/Hospital | 1 | 0 | 1 | 2010 |
| St. Jude Children's Hospital | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Bologna | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Milan | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2010 |
8 organizations
Page 1 / 1